ICICI Securities has upgraded Cipla to a BUY rating with a revised target price of Rs 1,550, implying a potential upside of nearly 19% from the current market price of Rs 1,306.

Motilal Oswal Financial Services has reiterated a BUY call on Laurus Labs, assigning a target price of Rs 1,280, implying an upside of nearly 19% from the current market price of Rs 1,076.

Axis Securities has reiterated its BUY recommendation on Biocon Ltd, setting a revised target price of Rs 435, even as the company reported a mixe

Jubilant Pharmova’s December quarter results reinforce a steady growth narrative even as near-term margin pressures temper earnings momentum.

Dr Reddy’s Laboratories is navigating a critical transition phase as legacy gains from gRevlimid taper off, even as the company lays the groundwork for its next multi-year growth cycle.

Gujarat Themis Biosyn Limited (GTBL), a niche pharmaceutical manufacturer specializing in fermentation-based intermediates, is entering a decisive phase of strategic evolution. BP Equities Pvt.